Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The J. David Gladstone Institutes currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, suggesting a narrow and specific focus for the current prosecution cycle. JANET L COPPINS is the busiest examiner, managing the 1 pending office action. Because the portfolio's active prosecution involves only 1 distinct examiner, the strategy is streamlined toward the requirements of a single individual. This allows for a more predictable interaction with the USPTO as there are no conflicting examiner styles to manage.
The concentration in a single art unit within Biotechnology & Pharmaceuticals means the applicant does not need to manage conflicting procedural expectations across different USPTO divisions. Success for this pending matter will rely on addressing the specific technical concerns raised by the sole examiner involved. Practitioners should focus on the established precedents within this 1 distinct art unit to ensure the application meets the specific standards applied to biotechnology disclosures. With only 1 pending office action, the institutes can focus their resources on securing this specific intellectual property asset without the administrative burden of a large, distributed portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267710 | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis | WANG, RUIXUE | 50d |
| 17765583 | METHODS FOR TARGETED CELL DEPLETION | RYAN, DOUGLAS CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267710 | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis | WANG, RUIXUE | 50d |
| 17765583 | METHODS FOR TARGETED CELL DEPLETION | RYAN, DOUGLAS CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267710 | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 50d | Pending | Jun 15, 2023 |
| 17765583 | METHODS FOR TARGETED CELL DEPLETION | RYAN, DOUGLAS CHARLES | 1635 | §102§103§112 | Final Rejection | — | Pending | Mar 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial